Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Operating expenses:
Research and development	$ 12,599	$ 10,241
General and administrative	8,263	8,264
Total operating expenses	20,862	18,505
Loss from operations	(20,862)	(18,505)
Other income (expense):
Interest income/(expense), net	1,284	(27)
Foreign exchange (loss)/gain, net	(52)	45
Change in fair value of 2022 USD Financing Warrants	(5,185)
Other income		36
Total other income/(expense), net	(3,953)	54
Net loss	(24,815)	(18,451)
Other comprehensive loss:
Gain/(loss) on foreign currency translation	14	(49)
Comprehensive loss	$ (24,801)	$ (18,500)
Net loss per common share, basic	$ (0.65)	$ (0.66)
Net loss per common share, diluted	$ (0.65)	$ (0.66)
Weighted-average common shares, basic	38,077,251	28,147,499
Weighted-average common shares, diluted	38,077,251	28,147,499